Biodesix, a molecular diagnostics company, has closed on $8.8 million in a follow-on sale of its Series D preferred shares. The funding was provided by existing shareholders of the company. Based in Boulder, CO, Biodesix provides physicians with diagnostic tests for earlier disease detection, disease monitoring and therapeutic guidance. Its latest funding will be used for ongoing development of its technology platform, as well as an expansion of sales and marketing efforts to support its first product, VeriStrat. Biodesix has a long history of VC funding, including a $20 million round of Series D financing in July 2011.